17 alpha-hydroxylase deficiency epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
Line 6: | Line 6: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
* The incidencee of congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency in the United States is approximately 1 per 100,000 individuals. | * The incidencee of congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency in the United States is approximately 1 per 100,000 individuals.<ref name="pmid25536973">{{cite journal| author=Auchus RJ| title=The classic and nonclassic concenital adrenal hyperplasias. | journal=Endocr Pract | year= 2015 | volume= 21 | issue= 4 | pages= 383-9 | pmid=25536973 | doi=10.4158/EP14474.RA | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25536973 }} </ref> | ||
===Age=== | ===Age=== | ||
* Patients of all age groups may develop congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. The mean age of diagnosis is infancy and childhood. | * Patients of all age groups may develop congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. The mean age of diagnosis is infancy and childhood. | ||
Line 12: | Line 12: | ||
* Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency affects male and female equally.<ref name="w"> Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. Wikipedia (2016. https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_17_alpha-hydroxylase_deficiency Accessed on February 4, 2016</ref> | * Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency affects male and female equally.<ref name="w"> Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. Wikipedia (2016. https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_17_alpha-hydroxylase_deficiency Accessed on February 4, 2016</ref> | ||
==References== | ==References== | ||
{{Reflist| | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] |
Revision as of 15:17, 9 February 2016
Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
17 alpha-hydroxylase deficiency epidemiology and demographics On the Web |
American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency epidemiology and demographics |
FDA on 17 alpha-hydroxylase deficiency epidemiology and demographics |
CDC on 17 alpha-hydroxylase deficiency epidemiology and demographics |
17 alpha-hydroxylase deficiency epidemiology and demographics in the news |
Blogs on 17 alpha-hydroxylase deficiency epidemiology and demographics |
Risk calculators and risk factors for 17 alpha-hydroxylase deficiency epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
The incidencee of congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency in the United States is approximately 1 per 100,000 individuals. Patients of all age groups may develop congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. The mean age of diagnosis is infancy and childhood.[1]
Epidemiology and Demographics
Incidence
- The incidencee of congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency in the United States is approximately 1 per 100,000 individuals.[2]
Age
- Patients of all age groups may develop congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. The mean age of diagnosis is infancy and childhood.
Gender
- Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency affects male and female equally.[1]
References
- ↑ 1.0 1.1 Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. Wikipedia (2016. https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_17_alpha-hydroxylase_deficiency Accessed on February 4, 2016
- ↑ Auchus RJ (2015). "The classic and nonclassic concenital adrenal hyperplasias". Endocr Pract. 21 (4): 383–9. doi:10.4158/EP14474.RA. PMID 25536973.